Prostate Cancer Clinical Trial

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

Summary

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer.

View Full Description

Full Description

Primary Objective: To determine feasibility of 68Ga-PSMA-11 PET/MRI and 68Ga-RM2 PET/MRI for evaluation of HIFU or HDR local therapy in patients with known prostate cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Known prostate cancer
Planned HIFU or HDR local therapy
Able to provide written consent
Karnofsky performance status of 50 (or Eastern Cooperative Oncology Group (ECOG) /World Health Organization (WHO) equivalent)

Exclusion Criteria:

Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam
Metallic implants (contraindicated for MRI)

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

14

Study ID:

NCT03949517

Recruitment Status:

Completed

Sponsor:

Andrei Iagaru

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford University
Stanford California, 94305, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

14

Study ID:

NCT03949517

Recruitment Status:

Completed

Sponsor:


Andrei Iagaru

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.